118 related articles for article (PubMed ID: 10974616)
1. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
Schruers K; Caycedo N; Overbeek T; Büchold H; Bourin M; Griez E
Eur Neuropsychopharmacol; 2000 Sep; 10(5):419-21. PubMed ID: 10974616
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
3. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
[TBL] [Abstract][Full Text] [Related]
4. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
Katzman MA; Duffin J; Shlik J; Bradwejn J
Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
[TBL] [Abstract][Full Text] [Related]
5. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
6. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
7. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
8. Effect of aging on cholecystokinin-induced panic.
Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
[TBL] [Abstract][Full Text] [Related]
9. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
[TBL] [Abstract][Full Text] [Related]
10. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
[TBL] [Abstract][Full Text] [Related]
11. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
McCann UD; Slate SO; Geraci M; Uhde TW
Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
[TBL] [Abstract][Full Text] [Related]
12. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
13. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
Kronenberg G; Schredl M; Fiedler K; Heuser I
Depress Anxiety; 2001; 14(2):141-4. PubMed ID: 11668667
[TBL] [Abstract][Full Text] [Related]
14. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
15. The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype.
Kellner M; Muhtz C; Demiralay C; Husemann J; Koelsch W; Yassouridis A; Wiedemann K
J Psychiatr Res; 2009 Mar; 43(6):642-8. PubMed ID: 18930474
[TBL] [Abstract][Full Text] [Related]
16. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
Koszycki D; Cox BJ; Bradwejn J
Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648
[TBL] [Abstract][Full Text] [Related]
17. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
18. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
19. Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers.
Aluoja A; Shlik J; Vasar V; Kingisepp PH; Jagomägi K; Vasar E; Bradwejn J
Psychiatry Res; 1997 Jan; 66(1):59-67. PubMed ID: 9061804
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.
Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R
Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
